7WVL
Structure of P4A2 Fab in complex with Spike-RBD from SARS-CoV-2
Summary for 7WVL
| Entry DOI | 10.2210/pdb7wvl/pdb |
| Descriptor | P4A2 Fab Light Chain, P4A2 Fab heavy chain, Spike protein S1, ... (4 entities in total) |
| Functional Keywords | fab, spike-rbd, complex, antiviral protein, viral protein-immune system complex, viral protein/immune system |
| Biological source | Mus musculus (Mouse) More |
| Total number of polymer chains | 3 |
| Total formula weight | 71534.84 |
| Authors | Narayanan, N.,Nair, D.T. (deposition date: 2022-02-10, release date: 2022-12-07, Last modification date: 2024-11-06) |
| Primary citation | Parray, H.A.,Narayanan, N.,Garg, S.,Rizvi, Z.A.,Shrivastava, T.,Kushwaha, S.,Singh, J.,Murugavelu, P.,Anantharaj, A.,Mehdi, F.,Raj, N.,Singh, S.,Dandotiya, J.,Lukose, A.,Jamwal, D.,Kumar, S.,Chiranjivi, A.,Dhyani, S.,Mishra, N.,Kumar, S.,Jakhar, K.,Sonar, S.,Panchal, A.K.,Tripathy, M.R.,Chowdhury, S.R.,Ahmed, S.,Samal, S.,Mani, S.,Bhattacharyya, S.,Das, S.,Sinha, S.,Luthra, K.,Batra, G.,Sehgal, D.,Medigeshi, G.R.,Sharma, C.,Awasthi, A.,Garg, P.K.,Nair, D.T.,Kumar, R. A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern. Plos Pathog., 18:e1010994-e1010994, 2022 Cited by PubMed Abstract: The emergence of new variants of SARS-CoV-2 necessitates unremitting efforts to discover novel therapeutic monoclonal antibodies (mAbs). Here, we report an extremely potent mAb named P4A2 that can neutralize all the circulating variants of concern (VOCs) with high efficiency, including the highly transmissible Omicron. The crystal structure of the P4A2 Fab:RBD complex revealed that the residues of the RBD that interact with P4A2 are a part of the ACE2-receptor-binding motif and are not mutated in any of the VOCs. The pan coronavirus pseudotyped neutralization assay confirmed that the P4A2 mAb is specific for SARS-CoV-2 and its VOCs. Passive administration of P4A2 to K18-hACE2 transgenic mice conferred protection, both prophylactically and therapeutically, against challenge with VOCs. Overall, our data shows that, the P4A2 mAb has immense therapeutic potential to neutralize the current circulating VOCs. Due to the overlap between the P4A2 epitope and ACE2 binding site on spike-RBD, P4A2 may also be highly effective against a number of future variants. PubMed: 36508467DOI: 10.1371/journal.ppat.1010994 PDB entries with the same primary citation |
| Experimental method | X-RAY DIFFRACTION (3 Å) |
Structure validation
Download full validation report
